News Search Results
Jul 23, 2026, 10:31 ET ALK Inhibitors Market Set for Transformational Growth at a CAGR of 4% During the Forecast Period (2026-2036) Backed by Next-Generation Targeted Therapies| DelveInsight
Methodology of Anaplastic Lymphoma Kinase (ALK) Inhibitors6Anaplastic Lymphoma Kinase (ALK) Inhibitors
More news about: DelveInsight Business Research, LLP
Jul 23, 2026, 09:50 ET Blood Cancer United Honors National Visionaries of the Year Winners for Extraordinary Impact
WASHINGTON, July 23, 2026 /PRNewswire/ -- Blood Cancer United®, formerly The Leukemia & Lymphoma Society, the leading nonprofit dedicated to curing blood cancers and improving the lives of patients and their families, today announced the national
More news about: Blood Cancer United
Jul 22, 2026, 10:31 ET CAR T-Cell Therapy for Non-Hodgkin Lymphoma Market Set for Robust Growth at a CAGR of ~7% Through 2036, Driven by Expanding Indications and Clinical Adoption | DelveInsight
Mantle cell lymphoma (MCL)Diffuse large B-cell lymphoma (DLBCL)Follicular lymphoma (FL)Primary mediastinal large B-cell lymphoma (PMBCL)Marginal zone lymphoma (MZL)Chronic lymphocytic leukemia/small-cell lymphocytic lymphoma (CLL/SLL)
More news about: DelveInsight Business Research, LLP
Jul 22, 2026, 07:37 ET Exposure to Weed Killer During Pregnancy May Increase Risk of Preterm Birth
medical reasons, such as preeclampsia or poor fetal growth.Past research has linked heavy use of the herbicide among farmworkers to non-Hodgkin lymphoma and other health concerns, but less is understood about everyday exposure, such as from eating foods with traces of the herbicide. More than 80 percent
More news about: NYU Grossman School of Medicine and NYU Langone Health
Jul 22, 2026, 07:00 ET Curis Announces Positive Emavusertib Update
will host a webcast on Wednesday, July 22 at 8:30 a.m. ET to discuss positive updated clinical data in the TakeAim Lymphoma study, its ongoing registrational study in Primary CNS Lymphoma (PCNSL), and provide updated guidance on year-end data in the TakeAim CLL study, its ongoing Phase 2 study in Chronic
More news about: Curis, Inc.
Jul 21, 2026, 13:00 ET Aetna Updates Coverage Policy to Include Home Phototherapy for Vitiligo
well, extending across the major chronic skin conditions it treats, including psoriasis, atopic dermatitis (eczema), vitiligo, and cutaneous T-cell lymphoma (most commonly mycosis fungoides). An estimated 26 million patients live with these conditions in the United States.3"Based on our
More news about: Phothera
Jul 21, 2026, 09:17 ET Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption
2026.About LYMPHIR™ (denileukin diftitox‑cxdl)LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. It is a recombinant fusion protein that combines the IL-2
More news about: Citius Oncology, Inc.
Jul 15, 2026, 07:00 ET Septa Pharmaceuticals Inc. Acquires CeeNU® (Lomustine) from Bristol Myers Squibb, Canada
(Lomustine) is an established and highly valued alkylating agent utilized primarily in the treatment of specific types of brain tumors and Hodgkin's lymphoma. By integrating this essential chemotherapy medication into its product lineup, Septa is reinforcing its footprint in the critical care and oncology
More news about: Septa Pharmaceuticals Inc.
Jul 15, 2026, 07:00 ET Septa Pharmaceuticals Inc. Acquires CeeNU® (Lomustine) from Bristol Myers Squibb, Canada
(Lomustine) is an established and highly valued alkylating agent utilized primarily in the treatment of specific types of brain tumors and Hodgkin's lymphoma. By integrating this essential chemotherapy medication into its product lineup, Septa is reinforcing its footprint in the critical care and oncology
More news about: Septa Pharmaceuticals Inc.
Jul 14, 2026, 19:30 ET Kelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Met Primary Endpoint
(KEYTRUDA®) as first‑line treatment for locally advanced or metastatic NSCLC who have PD-L1 TPS≥1% and are EGFR-negative and anaplastic lymphoma kinase (ALK)-negative has been accepted for review by the NMPA, and has entered the priority review and approval process. As of today, Kelun-Biotech
More news about: Kelun-Biotech
Jul 14, 2026, 08:00 ET HUYABIO International Delivers Significant Landmark Phase 3 Results in Advanced Melanoma
patients across 15 countries, representing HUYABIO's largest oncology study to date. HBI-8000 is an oral drug that has received regulatory approval for lymphoma in China and Japan. It has been prescribed to over 90,000 patients and so has a well established safety record."These results represent an
More news about: HUYABIO International
Jul 14, 2026, 06:00 ET Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibody
pain, and fatigue. In some patients, organ involvement can include kidney or lung dysfunction, and there is an increased risk of non-Hodgkin's B-cell lymphoma. More than half of patients develop moderate-to-severe disease, with a burden comparable to other serious autoimmune conditions. About Innovent
More news about: Innovent Biologics
Jul 14, 2026, 02:00 ET Dizal Announces Global Exclusive License Agreement with AstraZeneca for Zegfrovy
for the treatment of NSCLC with EGFR exon20ins. Golidocitinib is approved in China for the treatment of relapsed and refractory peripheral T cell lymphoma. Birelentinib, a BBB-penetrant LYN/BTK dual inhibitor, is currently in pivotal studies for various hematological diseases.
More news about: Dizal
Jul 10, 2026, 16:33 ET HealthTree Foundation Announces the Appointment of Lisa Gray to Its Board of Directors
program and staff, generating $20M+ annually. Prior to that, she held a senior vice president role at Blood Cancer United (formerly the Leukemia & Lymphoma Society), helping to drive revenue growth and deepen philanthropic support.Diagnosed with multiple myeloma in 2023, Lisa has since dedicated
More news about: HealthTree Foundation
Jul 09, 2026, 13:09 ET Stem Cell Banking Market Surges to USD 28.9 Billion by 2033, Propelled by 12.4% CAGR - Verified Market Reports®
clinical standpoint, hematopoietic stem cell transplantation (HSCT) remains the gold standard for treating blood malignancies including leukemia, lymphoma, and aplastic anemia. The World Health Organization estimates that cancer burden globally will reach 35 million new cases annually by 2050, a trajectory
More news about: Verified Market Reports
Jul 09, 2026, 10:31 ET Systemic Lupus Erythematosus Market at a Turning Point as 6 Late-Stage Emerging Therapies Set to Redefine Treatment Landscape | DelveInsight
(GAZYVA/GAZYVARO)TSLP inhibitorObinutuzumab is a glycoengineered monoclonal antibody designed to target the CD20 protein expressed on the surface of lymphoma and leukemia cells. As a type II anti-CD20 antibody, it exhibits greater antibody-dependent cellular cytotoxicity and stronger direct cell-killing
More news about: DelveInsight Business Research, LLP
Jul 09, 2026, 08:00 ET Trinity Appoints Tina Durocher-Murphy as Chief People Officer
organizations including the American Red Cross, where she served as Board Chair for Central North Carolina, Dress for Success, and The Leukemia & Lymphoma Society's Light the Night campaign. She earned a bachelor's degree in psychology from the University of Wisconsin–Stevens Point and a master's degree
More news about: Trinity
Jul 06, 2026, 17:58 ET Active Motif Announces Exclusive Global Distribution Agreement with Arima Genomics for Advanced 3D Genomics Solutions
conventional approaches can miss or incompletely characterize. Through its Aventa clinical testing brand, Arima offers testing for solid tumors and lymphoma from its CLIA-certified laboratory in Orlando, Florida. Learn more at
More news about: Active Motif
Jul 06, 2026, 17:44 ET Active Motif Announces Exclusive Global Distribution Agreement with Arima Genomics for Advanced 3D Genomics Solutions
conventional approaches can miss or incompletely characterize. Through its Aventa clinical testing brand, Arima offers testing for solid tumors and lymphoma from its CLIA-certified laboratory in Orlando, Florida. Learn more at
More news about: Active Motif
Jul 06, 2026, 13:45 ET AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
refractory (R/R) follicular lymphoma (FL). The approval is based on results from the pivotal Phase 3 EPCORE® FL-1 trial, which evaluated fixed-duration TEPKINLY in combination with R2 compared to standard of care R2. "Follicular lymphoma is a persistent form of cancer
More news about: AbbVie
Jul 06, 2026, 13:45 ET AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
refractory (R/R) follicular lymphoma (FL). The approval is based on results from the pivotal Phase 3 EPCORE® FL-1 trial, which evaluated fixed-duration TEPKINLY in combination with R2 compared to standard of care R2. "Follicular lymphoma is a persistent form of cancer
More news about: AbbVie
Jul 06, 2026, 09:30 ET Curis Consents First Six Patients in TakeAim CLL Study
inhibitor. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) of emavusertib in combination with the BTK inhibitor, ibrutinib, in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) and in the TakeAim CLL Phase 2 study (CA-4948-203) of
More news about: Curis, Inc.
Jul 02, 2026, 13:21 ET After Durnell: Why the Fight Against Pesticides and their Health Harms Is Entering a New Chapter
right on top of those crops. People who spent years spraying what they believed was a "safe" weedkiller, before being diagnosed with non-Hodgkin's lymphoma.For more than a decade, juries across the country have listened to their stories. Again and again, they concluded that Monsanto (now Bayer)
More news about: The Center For Food Safety
Jul 01, 2026, 16:05 ET ADC Therapeutics Announces New Employee Inducement Grant
accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy.Headquartered
More news about: ADC Therapeutics SA
Jul 01, 2026, 11:00 ET Blood Cancer United Welcomes New Board Members & Philanthropy Leadership
WASHINGTON, July 1, 2026 /PRNewswire/ -- Blood Cancer United®, formerly The Leukemia & Lymphoma Society, has appointed four new members to its
More news about: BLOOD CANCER UNITED, INC.